184 related articles for article (PubMed ID: 32911509)
1. The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
Español AJ; Salem A; Di Bari M; Cristofaro I; Sanchez Y; Tata AM; Sales ME
PLoS One; 2020; 15(9):e0226450. PubMed ID: 32911509
[TBL] [Abstract][Full Text] [Related]
2. Effect of low dose metronomic therapy on MCF-7 tumor cells growth and angiogenesis. Role of muscarinic acetylcholine receptors.
Salem AR; Martínez Pulido P; Sanchez F; Sanchez Y; Español AJ; Sales ME
Int Immunopharmacol; 2020 Jul; 84():106514. PubMed ID: 32311671
[TBL] [Abstract][Full Text] [Related]
3. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
[TBL] [Abstract][Full Text] [Related]
4. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
5. Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer.
Sales ME
Curr Pharm Des; 2016; 22(14):2170-7. PubMed ID: 26924207
[TBL] [Abstract][Full Text] [Related]
6. The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells.
Lucianò AM; Perciballi E; Fiore M; Del Bufalo D; Tata AM
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182656
[TBL] [Abstract][Full Text] [Related]
7. M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells.
Pacini L; De Falco E; Di Bari M; Coccia A; Siciliano C; Ponti D; Pastore AL; Petrozza V; Carbone A; Tata AM; Calogero A
Cancer Biol Ther; 2014; 15(11):1489-98. PubMed ID: 25482946
[TBL] [Abstract][Full Text] [Related]
8. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
9. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
11. Participation of non-neuronal muscarinic receptors in the effect of carbachol with paclitaxel on human breast adenocarcinoma cells. Roles of nitric oxide synthase and arginase.
Español AJ; Salem A; Rojo D; Sales ME
Int Immunopharmacol; 2015 Nov; 29(1):87-92. PubMed ID: 25812766
[TBL] [Abstract][Full Text] [Related]
12. M2 receptors exert analgesic action on DRG sensory neurons by negatively modulating VR1 activity.
De Angelis F; Marinelli S; Fioretti B; Catacuzzeno L; Franciolini F; Pavone F; Tata AM
J Cell Physiol; 2014 Jun; 229(6):783-90. PubMed ID: 24166293
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
Zhang M; Chen C; Su F; Huang Z; Li X; Li X
Technol Cancer Res Treat; 2017 Oct; 16(5):609-619. PubMed ID: 27573201
[TBL] [Abstract][Full Text] [Related]
14. M2 muscarinic receptor activation inhibits cell proliferation and migration of rat adipose-mesenchymal stem cells.
Piovesana R; Melfi S; Fiore M; Magnaghi V; Tata AM
J Cell Physiol; 2018 Jul; 233(7):5348-5360. PubMed ID: 29227527
[TBL] [Abstract][Full Text] [Related]
15. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
[TBL] [Abstract][Full Text] [Related]
16. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
Amith SR; Wilkinson JM; Baksh S; Fliegel L
Oncotarget; 2015 Jan; 6(2):1262-75. PubMed ID: 25514463
[TBL] [Abstract][Full Text] [Related]
17. M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells.
Ferretti M; Fabbiano C; Di Bari M; Conte C; Castigli E; Sciaccaluga M; Ponti D; Ruggieri P; Raco A; Ricordy R; Calogero A; Tata AM
J Cell Mol Med; 2013 Apr; 17(4):552-66. PubMed ID: 23490231
[TBL] [Abstract][Full Text] [Related]
18. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis.
Karginova O; Weekley CM; Raoul A; Alsayed A; Wu T; Lee SS; He C; Olopade OI
Mol Cancer Ther; 2019 May; 18(5):873-885. PubMed ID: 30824611
[TBL] [Abstract][Full Text] [Related]
20. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
